SCHEDULE: Decheng Capital Maintains Significant Stake in Beyondspring

Decheng Capital and its affiliates, including Dr. Xiangmin Cui, report a combined 9.2% beneficial ownership in Beyondspring Inc. as of December 31, 2025.

Summary

• Decheng Capital Management III (Cayman), LLC, Decheng Capital China Life Sciences USD Fund III, L.P., Decheng Capital China Life Sciences USD Fund II, L.P., Decheng Capital Management II (Cayman), LLC, Decheng Capital Global Healthcare Fund (Master), LP, Decheng Capital Global Healthcare GP, LLC, and Dr. Xiangmin Cui are the reporting persons.
• As of December 31, 2025, Dr. Xiangmin Cui beneficially owns 3,800,702 ordinary shares of Beyondspring Inc., representing 9.2% of the class.
• This ownership includes 1,448,293 shares held by Fund III (3.5%), 1,617,409 shares held by Fund II (3.9%), and 735,000 shares held by Healthcare (1.8%).
• Dr. Cui shares voting and investment authority over all these shares as the sole manager of GP II and GP III, and the indirect managing member and ultimate beneficial owner of Healthcare GP.
• The percentage of class is based on 41,122,320 ordinary shares outstanding as of November 18, 2025, as reported in Beyondspring Inc.'s prospectus supplement dated November 17, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as it confirms continued significant institutional ownership by a specialized life sciences fund, which can imply ongoing support and belief in the company's long-term prospects.

Positives

• The filing confirms a significant institutional investor, Decheng Capital, and its principal, Dr. Xiangmin Cui, maintain a substantial beneficial ownership stake of 9.2% in Beyondspring Inc., indicating continued confidence in the company.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Beyondspring Inc.'s operations or financial performance.

Industry Context

StockSavvy.ai notes that Decheng Capital is a prominent life sciences venture capital firm. Their continued significant stake in Beyondspring Inc., a biopharmaceutical company, suggests ongoing strategic interest in the company's pipeline or market position within the competitive biotech sector. Such institutional backing can be a positive signal for other investors, particularly in a capital-intensive industry like pharmaceuticals.

Comparison to Industry Standards

• A 9.2% beneficial ownership stake by a single institutional investor and its principal is a substantial position, often seen in early-stage or growth-oriented biotechnology companies where venture capital firms play a significant role in funding and strategic guidance.
• This level of ownership is comparable to other specialized life sciences funds taking meaningful, but passive, positions in their portfolio companies, such as Flagship Pioneering's stakes in its incubated companies or OrbiMed's investments in emerging biotechs.

Stakeholder Impact

• Shareholders: The continued significant stake by Decheng Capital and Dr. Cui may provide a level of confidence, signaling that a major institutional investor remains committed to Beyondspring Inc.
• Management: The presence of a large, specialized investor like Decheng Capital can influence strategic decisions, though this filing indicates a passive investment purpose.

Key Dates

Recommendation

The Schedule 13G filing primarily provides an update on beneficial ownership by Decheng Capital and Dr. Xiangmin Cui. While confirming a significant institutional stake, it does not contain new operational or financial information about Beyondspring Inc. that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, pending further company-specific news or financial disclosures.

Keywords

Beyondspring Inc., Decheng Capital, Xiangmin Cui, Schedule 13G, Beneficial Ownership, Institutional Investor, Ordinary Shares, Biotechnology, Life Sciences